Maj Friberg Birkedal

Maj Friberg Birkedal

Auto-generated profile, based on publicly available information

Maj Friberg Birkedal

Haemophilia Treatment Centre, Rigshospitalet , Copenhagen , Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in The Journal of Haemophilia Practice
Verified
Journal Article
Open access
PDF file
SCSteve Chaplin
Steve Chaplin
MBMaj Friberg Birkedal
Maj Friberg Birkedal
ECErica Crilly
Erica Crilly
SFSimon Fletcher
Simon Fletcher
SBSara García Barcenilla
Sara García Barcenilla
NUNanda Uitslager
Nanda Uitslager
Introduction: Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes. Current clinical practice reduces the risk of bleeds, making differences difficult to measure. We surveyed specialist haemophilia nurses to discern their opinions about the impact of haemophilia B compared to haemophilia A. Methods: Between July and September 2020, European and Canadian nurses were invited to complete an online survey (25 questions) about perceptions of management and treatment of haemophilia B. Results: Fifty-nine nurses (46 European, 13 Canadian) completed the survey. Bleeding was reported as different in haemophilia B by 37% of respondents, and treatment as different by over half. Opinions and experience around using extended half-life (EHL) products varied. Self-reported confidence in using EHL products was rated at a mean of 7.1 (range 3–10) with 47% believing these would remain the optimal treatment in 2025. Conclusion: Some nurses believe haemophilia A and B are managed differently. Variations in experience and levels of confidence in the use of EHL products, combined with a belief that these products will remain an optimal treatment for haemophilia B for the next five years, indicates a need for education to promote confidence and competence.

1 January 2024 in The Journal of Haemophilia Practice
Verified
Journal Article
Open access
PDF file
MBMaj Friberg Birkedal
Maj Friberg Birkedal
Background: The introduction of emicizumab as prophylactic subcutaneous (SC) administered treatment for people with haemophilia A has revolutionised its treatment and care; SC injection and the infrequent treatment intervals that can be achieved with emicizumab reduces treatment burden and interference in daily life. The efficacy and safety of emicizumab have been investigated in the Haven 1-7 trials. In contrast to the 4% of enrolled patients experiencing pain at the injection site across all seven trials, 11 out of 16 families at our treatment centre reported pain-related distress in administering emicizumab to their children, despite the application of local analgesia. Aim: The study aimed to retrospectively evaluate whether using the Neria ™ Guard infusion set, a single-use medical device for SC drug delivery that allows for slow infusion, reduced pain and distress in children receiving emicizumab. Methods: This single-centre retrospective study included 11 paediatric patients whose families were introduced to the Neria ™ Guard infusion set with the intent of reducing pain and distress. Plasma emicizumab values were tested after the introduction in relation to routine clinical check-ups in all patients. Data was collected retrospectively from patient files. According to local regulations ethical approval and consent was not necessary. Results: Parents/caregivers had no difficulty learning how to use the system; a single demonstration was sufficient in all cases. All families reported a reduction or complete resolution of pain and distress in relation to emicizumab injection after the introduction of Neria ™ Guard, and all families have continued using the device. Plasma levels of emicizumab were sustained within the target therapeutic range. Conclusion: There is a need for more recognition of and research into the prevalence of pain and distress among children receiving treatment with emicizumab, and a need for a validated and stability tested solution to alleviate this. Neria ™ Guard has proven to be effective in the reduction of pain and distress in our clinic.